Literature DB >> 527637

The pharmacokinetics of diclofenac sodium following intravenous and oral administration.

J V Willis, M J Kendall, R M Flinn, D P Thornhill, P G Welling.   

Abstract

The pharmacokinetics of diclofenac were examined following single rapid intravenous injection and also following single oral doses to healthy female volunteers. After intravenous injection plasma levels of diclofenac fell rapidly and were below the limits of detection at 5.5 h postdosing. Individual drug profiles were described by a triexponential function and mean half-lives of the three exponential phases were 0.05, 0.26 and 1.1 h. After oral doses of enteric-coated tablets, the lag time between dosing and the appearance of drug in plasma varied between 1.0 and 4.5 h. However once drug absorption had commenced similar plasma drug profiles were obtained in different individuals. Peak plasma diclofenac levels ranged from 1.4 to 3.0 microgram . ml-1. The mean terminal drug half-life in plasma was 1.8 h after oral doses. This value was not significantly greater than the value of 1.1 h following intravenous doses. Fifty percent of orally dosed diclofenac did not reach the systemic circulation due, predominantly, to first-pass metabolism.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 527637     DOI: 10.1007/BF00568201

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Do you need a pharmacokinetic model, and, if so, which one?

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1975-12

2.  The binding of penicillin antibiotics to a human liver protein.

Authors:  M L Kornguth; R A Monson; C M Kunin
Journal:  Arch Biochem Biophys       Date:  1976-05       Impact factor: 4.013

3.  [New aspects of inflammation prevention by means of non-steroid antiphlogistics: the effect of Voltaren].

Authors:  P Krupp; B Exer; R Menassé; R Ziel
Journal:  Schweiz Med Wochenschr       Date:  1975-05-17

4.  Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren.

Authors:  W Riess; H Stierlin; P Degen; J W Faigle; A Gérardin; J Moppert; A Sallmann; K Schmid; A Schweizer; M Sulc; W Theobald; J Wagner
Journal:  Scand J Rheumatol Suppl       Date:  1978

5.  Binding of antibiotics to a soluble protein from rat liver.

Authors:  M L Kornguth; R A Monson; C M Kunin
Journal:  J Infect Dis       Date:  1974-05       Impact factor: 5.226

6.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

7.  Sodium (o-((2,6-dichlorophenyl)-amino)-phenyl)-acetate (GP 45 840), a new non-steroidal anti-inflammatory agent.

Authors:  P J Krupp; R Menassé-Gdynia; A Sallmann; G Wilhelmi; R Ziel; R Jaques
Journal:  Experientia       Date:  1973-04-15

8.  Pharmacological properties of diclofenac sodium and its metabolites.

Authors:  R Menassé; P R Hedwall; J Kraetz; C Pericin; L Riesterer; A Sallmann; R Ziel; R Jaques
Journal:  Scand J Rheumatol Suppl       Date:  1978

9.  Quantitative assay of diclofenac in biological material by gas-liquid chromatography.

Authors:  U P Geiger; P H Degen; A Sioufi
Journal:  J Chromatogr       Date:  1975-09-03

10.  Pharmacokinetic studies on diclofenac sodium in young and old volunteers.

Authors:  J V Willis; M J Kendall
Journal:  Scand J Rheumatol Suppl       Date:  1978
View more
  66 in total

1.  A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.

Authors:  Emilie Hénin; Martin Bergstrand; Joseph F Standing; Mats O Karlsson
Journal:  AAPS J       Date:  2012-06       Impact factor: 4.009

2.  Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS.

Authors:  Georgia Charkoftaki; Aristides Dokoumetzidis; Georgia Valsami; Panos Macheras
Journal:  Pharm Res       Date:  2012-07-04       Impact factor: 4.200

3.  An inactivation stabilizer of the Na+ channel acts as an opportunistic pore blocker modulated by external Na+.

Authors:  Ya-Chin Yang; Chung-Chin Kuo
Journal:  J Gen Physiol       Date:  2005-04-11       Impact factor: 4.086

Review 4.  Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

5.  Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).

Authors:  Christian Maass; Cynthia L Stokes; Linda G Griffith; Murat Cirit
Journal:  Integr Biol (Camb)       Date:  2017-04-18       Impact factor: 2.192

6.  Application of dual radiotelemetric technique in studying drug-drug interaction between diclofenac sodium and ranitidine HCl in volunteers.

Authors:  C Alioth; R A Blum; D T D'Andrea; G M Kochak; L Teng; B A Ziehmer; J J Schentag; K K Chan
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

Review 7.  Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-10       Impact factor: 9.546

8.  Pharmacokinetics of diclofenac and misoprostol when administered alone or as a combination product.

Authors:  A Karim
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 9.  Sex-related differences in drug disposition in man.

Authors:  K Wilson
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

10.  Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate.

Authors:  H Derendorf; G Mullersman; J Barth; A Grüner; H Möllmann
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.